Abstract:
Embodiments of the present disclosure relate to a method and an apparatus for providing configuration for serving terminal device. A first aspect of the present disclosure provides a method performed by a first network function. The method may comprise: transmitting (S201) to a second network function a request for providing at least one service parameter for a UE or a group of UEs, and receiving (S202) from the second network function a response about whether the request is authorized. According to embodiments of the present disclosure, after a first network function transmits a request for providing at least one service parameter for a terminal device, the first network function may be aware about whether the request is authorized.
Abstract:
Embodiments of the present disclosure provide external parameters for an Application Function (AF) session in a more efficient and dynamic manner. A method of operation of the AF comprises transmitting a request to a Network Exposure Function (NEF). Herein, the request comprises information indicating one or more User Equipments (UEs). Herein, the one or more UEs may include a UE that has not established a Protocol Data Unit (PDU) session yet. The information indicating the one or more UEs includes a UE ID for a specific UE, a group UE ID for multiple UEs, or a UE indication indicating any UE, and optionally includes one or more conditions defining geographic zones and/or time windows.
Abstract:
The present invention is directed to 3-heteroaryl pyrrolidine and piperidine compounds which are agonists of orexin receptors. The present invention is also directed to uses of the compounds described herein in the potential treatment or prevention of neurological and psychiatric disorders and diseases in which orexin receptors are involved. The present invention is also directed to compositions comprising these compounds. The present invention is also directed to uses of these compositions in the potential prevention or treatment of such diseases in which orexin receptors are involved.
Abstract:
In a first aspect of the disclosure, a method performed by an AAA server (103) of authenticating a non- SIM mobile terminal (111) with a wireless network (100) is provided. The method comprises receiving (S201) a request for service of the non-SIM mobile terminal (111), authenticating (S202) the non-SIM mobile terminal (111), submitting (S203) a request for subscriber profile data associated with the non-SIM mobile terminal (111) to an HSS (105), the subscriber profile data request comprising an indication that the non-SIM mobile terminal (111) has been authenticated by the AAA server (103), and receiving (S204) from the HSS (105), in response to the indication that the non-SIM mobile terminal (111) has been authenticated, the requested subscription profile data.
Abstract:
The present invention relates to 2'-Methyl Substituted Nucleoside Derivatives of Formula (I): and pharmaceutically acceptable salts thereof, wherein R, R 1 , R 2 and R 3 , are as defined herein. The present invention also relates to compositions comprising at least one 2'-Methyl Substituted Nucleoside Derivative, and methods of using the 2'-Methyl Substituted Nucleoside Derivatives for treating or preventing HCV infection in a patient.
Abstract:
Novel compounds of the structural formula (I) are activators of AMP-protein kinase and may be useful in the treatment, prevention and suppression of diseases mediated by the AMPK activated protein kinase. The compounds of the present invention may be useful in the treatment of Type 2 diabetes, hyperglycemia, metabolic syndrome, obesity, hypercholesterolemia, and hypertension.
Abstract:
Novel compounds of the structural formula (I) are activators of AMP-protein kinase and may be useful in the treatment, prevention and suppression of diseases mediated by the AMPK-activated protein kinase. The compounds of the present invention may be useful in the treatment of Type 2 diabetes, hyperglycemia, metabolic syndrome, obesity, hypercholesterolemia, and hypertension.
Abstract:
Novel compounds of structural formula (I) are activators of AMP-protein kinase and are useful in the treatment, prevention and suppression of diseases mediated by the AMPK-activated protein kinase. The compounds of the present invention are useful in the treatment of Type 2 diabetes, hyperglycemia, metabolic syndrome, obesity, hypercholesterolemia, and hypertension.
Abstract:
A Connector Position Assurance (CPA) device for ensuring mating of a male header connector with a female housing includes a body portion, a first arm, and a second arm. The first arm is attached to the body portion, extended from the body portion, and includes a locking groove proximate a distal end thereof. The second arm, which includes a locking latch, is spaced apart from the first arm, attached to the body portion, and extended from the body portion. When the CPA device is guided along the female housing, the locking groove and the locking latch lock onto complementary protrusions on the female housing in a pre-lock position, only to be dislodged upon contact of a sloped surface at the distal end of the first arm with the male header connector during insertion of the male header connector into the female housing to proceed to a final-lock position.
Abstract:
The present invention relates to compounds of the general formula (I): wherein ring A, ring B, G, R 3 , Z, L 1 , and L 2 are selected independently of each other and are as defined herein, to compositions comprising the compounds, and to methods of using the compounds as glucagon receptor antagonists and for the treatment or prevention of type 2 diabetes and conditions related thereto.